Mesenchymal Stem Cells in Neurodegenerative Disorders: A Review of Current Evidence and Therapeutic Perspectives
,
Abstract
Disorders of the central nervous system (CNS), including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, cerebral palsy, stroke, and spinal cord injury, are associated with neuronal damage, neuronal loss, inflammation, and impaired neurological function and remain major challenges in medicine. Despite advances in pharmacological, surgical, and rehabilitative interventions, many of these disorders lack definitive or fully effective treatments. In recent years, stem cell-based therapies have received considerable attention as potential approaches for neural repair and functional recovery. Mesenchymal stem cells (MSCs) have attracted particular interest because of their distinctive biological properties, including their capacity for differentiation, secretion of neurotrophic factors, immunomodulatory and anti-inflammatory effects, and migration toward injured tissues. Compared with other stem cell types, including neural stem cells, embryonic stem cells, and induced pluripotent stem cells, MSCs offer several potential advantages, such as relatively easy accessibility, availability from multiple sources, including bone marrow, adipose tissue, and umbilical cord blood, and fewer ethical concerns. This narrative review examines published studies on the application of MSCs in neurological disorders, with particular emphasis on their biological characteristics, potential mechanisms of action, cellular sources, and advantages compared with other stem cell types. The available evidence regarding the use of MSCs in neurodegenerative diseases and other CNS disorders, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, stroke, and spinal cord injury, is also reviewed and discussed. Overall, available evidence suggests that MSCs may support neural function and repair through neurotrophic, anti-inflammatory, immunomodulatory, and regenerative mechanisms. However, despite encouraging findings from preclinical studies and some clinical investigations, current clinical evidence remains limited and heterogeneous. Differences in cell source, cell preparation and administration, dosage, treatment timing, and long-term outcomes may influence therapeutic effects. Therefore, well-designed and adequately powered clinical studies are needed to establish the efficacy and safety of MSC-based therapies and to determine their potential advantages over other cell-based approaches.
1. Ankeny DP, McTigue DM, Jakeman LB. Bone marrow transplants provide tissue protection and directional guidance for axons after contusive spinal cord injury in rats. Exp Neurol. 2004;190(1):17–31.
2. Wu YY, Gao YM, Feng T, et al. Enhancing functional recovery after spinal cord injury through neuroplasticity: a comprehensive review. Int J Mol Sci. 2025;26(14):6596.
3. Mohammadsadeghi H. The role of astrocytes in the central nervous system: physiological and pathophysiological conditions. Neurosci J Shefaye Khatam. 2021;9(2):119–39.
4. Sahab Negah S, Aligholi H, Mohammad Sadeghi S, et al. P39: Effect of Injured Brain Extract on Proliferation of Neural Stem/Progenitor Cells Cultured in a 3-dimensional Scaffold. Neurosci J Shefaye Khatam. 2014;2(4):Suppl. 3.
5. Hajali V, Moradi HR, Sahab Negah S. Neurotransmitters Play as a Key Role in Adult Neurogenesis. Neurosci J Shefaye Khatam. 2018;6(4):61–74.
6. Jabbarian M, Darvishi M, Barati DP, et al. Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells into Neuron-Like Cells Affected by Extract of Ginger Officinale. 2017; 5(2):1-10.
7. Webb AA, Ngan S, Fowler D. Spinal cord injury II: Prognostic indicators, standards of care, and clinical trials. Can Vet J. 2010;51(6):598-604.
8. Aktan F, Henness S, Tran VH, et al. Gingerol metabolite and a synthetic analogue CapsarolTM inhibit macrophage NF-κB-mediated iNOS gene expression and enzyme activity. Planta Med. 2006;72(08):727–34.
9. Rahman MM, Islam MR, Islam MT, et al. Stem cell transplantation therapy and neurological disorders: current status and future perspectives. Biology (Basel). 2022;11(1):147.
10. Chen S, et al. Clinical translational research on stem cell products: prospects and challenges. Signal Transduct Target Ther. 2026;11(1):178.
11. Yusoff NA, Abd Hamid Z, Budin SB, et al. Hematopoietic stem cell discovery: unveiling the historical and future perspective of colony-forming units assay. PeerJ. 2025;13: e18854.
12. Gage FH. Mammalian neural stem cells. Science. 2000;287(5457):1433–8.
13. Silvestris DA, De Luisi A 1 , Lucia Capobianco D, et al. Single-cell transcriptomic profiling of human fetal neural stem cells isolated from the subventricular zone. Front Cell Dev Biol. 2026;14:1740851.
14. Allami M, Al-Shammari AM, Neshati Z. Generation and characterization of Purkinje-like cells from differentiated mouse bone marrow mesenchymal stem cells. Iranian J War Pub Health. 2025;17(2):113-121.
15. Stafford N. Germany liberalises law on stem cell research. BMJ. 2008;336(7649):851.
16. Takabatake K, Tsujigiwa H , Song Yu, et al. The role of bone marrow-derived cells during ectopic bone formation of mouse femoral muscle in GFP mouse bone marrow transplantation model. Int J Med Sci. 2018;15(8):748–755.
17. Chang D, Fan T, Gao S, et al. Application of mesenchymal stem cell sheet to treatment of ischemic heart disease. Stem Cell Res Ther. 2021;12(1):384.
18. Lee BC, Kim HS, Shin TH, et al. PGE2 maintains self-renewal of human adult stem cells via EP2-mediated autocrine signaling and its production is regulated by cell-to-cell contact. Sci Rep. 2016;6:26298.
19. Tang Y, Zhou Y, Li HJ. Advances in mesenchymal stem cell exosomes: a review. Stem Cell Res Ther. 2021;12(1):71.
20. Margiana R, Markov A, Zekiy AO, et al. Clinical application of mesenchymal stem cell in regenerative medicine: a narrative review. Stem Cell Res Ther. 2022;13(1):366.
21. Hmadcha A, Martin-Montalvo A, Gauthier BR, et al. Therapeutic potential of mesenchymal stem cells for cancer therapy. Front Bioeng Biotechnol. 2020;8:43.
22. Haus DL, López-Velázquez L, Gold EM, et al. Transplantation of human neural stem cells restores cognition in an immunodeficient rodent model of traumatic brain injury. Exp Neurol. 2016;281:1–16.
23. Alnaji Z, Mohammed EJ, Allami M, et al. Multidrug-resistant Pseudomonas aeruginosa in wound and burn infections: resistance, virulence, serotypes and biofilm characteristics in Baghdad. J Umm Al-Qura Univ Appl Sci. 2026:1-15
24. Zhang C, Saatman KE, Royo NC, et al. Delayed transplantation of human neurons following brain injury in rats: a long-term graft survival and behavior study. J Neurotrauma. 2005;22(12):1456–74.
25. Clervius H, Baig M, Mahavadi A, et al. Human neural stem cell transplants to address multiple pathologies associated with traumatic brain injury. Neural Regen Res. 2019;14(10):1699–700.
26. Firouzabadi ED, Allami M, Mohammed EJ, et al. Detection of novel PPP1R1B::STARD3 fusion transcript in acute myeloid leukemia: a case report. J Med Case Rep. 2024;18(1):269.
27. Afhami M, Behnam-Rassouli M, Gorji A, et al. Isolation and culture of neural stem/progenitor cells from the hippocampal dentate gyrus of young adult and aged rats. Bio Protoc. 2023;13(19): e4843.
28. Baig MH, Ahmad K, Rabbani G, et al. Use of peptides for the management of Alzheimer’s disease: diagnosis and inhibition. Front Aging Neurosci. 2018;10:21.
29. Engel M, Do-Ha D, Munoz SS, et al. Common pitfalls of stem cell differentiation: a guide to improving protocols for neurodegenerative disease models and research. Cell Mol Life Sci. 2016;73(19):3693–709.
30. Jones SV, Kounatidis I. Nuclear factor-kappa B and Alzheimer disease, unifying genetic and environmental risk factors from cell to humans. Front Immunol. 2017;8:1805.
31. Shen Z, Li X, Bao X, et al. Microglia‐targeted stem cell therapies for Alzheimer disease: A preclinical data review. J Neurosci Res. 2017;95(12):2420–9.
32. Ebrahimikia Y, Darabi S, Rajaei F. Roles of Stem Cells in the Treatment of Alzheimer’s Disease. J Shahid Sadoughi Univ Med Sci. 2020;28(3):2431-2441.
33. Ra JC, Shin IS, Kim SH, et al. Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. Stem Cells Dev. 2011;20(8):1297–308.
34. Lee J, Kuroda S, Shichinohe H, et al. Migration and differentiation of nuclear fluorescence‐labeled bone marrow stromal cells after transplantation into cerebral infarct and spinal cord injury in mice. Neuropathology. 2003;23(3):169–80.
35. Kim KS, Kim HS, Park JM, et al. Long-term immunomodulatory effect of amniotic stem cells in an Alzheimer’s disease model. Neurobiol Aging. 2013;34(10):2408–20.
36. Naaldijk Y, Jaeger C, Fabian C, et al. Effect of systemic transplantation of bone marrow‐derived mesenchymal stem cells on neuropathology markers in APP/PS 1 Alzheimer mice. Neuropathol Appl Neurobiol. 2017;43(4):299–314.
37. Faghihi A, Joghataei MT, Darabi S, et al. Evaluation of Behavioral Effects of Trans-Resveratrol in the Hemi-Parkinsonian Rat Model. Anat Sci J. 2007;5(19):107–14.
38. Rangel-Barajas C, Coronel I, Florán B. Dopamine receptors and neurodegeneration. Aging Dis. 2015;6(5):349-368.
39. Zhang J, Wang X, Li J, et al. The preclinical research progress of stem cells therapy in Parkinson’s disease. Biomed Res Int. 2016;2016(1):5683097.
40. Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg psychiatry. 2008;79(4):368–76.
41. Nooraei MS, Noori-Zadeh A, Darabi S, et al. Low level of autophagy-related gene 10 (ATG10) expression in the 6-hydroxydopamine rat model of Parkinson’s disease. Iran Biomed J. 2018;22(1):15-21.
42. Choi H, Koh SH. Understanding the role of glycogen synthase kinase-3 in L-DOPA-induced dyskinesia in Parkinson’s disease. Expert Opin Drug Metab Toxicol. 2018;14(1):83–90.
43. Darabi S, Tiraihi T, Delshad A, et al. In vitro non-viral murine pro-neurotrophin 3 gene transfer into rat bone marrow stromal cells. J Neurol Sci. 2017;375:137–45.
44. Barachini S, Trombi L, Danti S, et al. Morpho-functional characterization of human mesenchymal stem cells from umbilical cord blood for potential uses in regenerative medicine. Stem Cells Dev. 2009;18(2):293–305.
45. Abd-Elhalem SS, Haggag NZ, El-Shinnawy NA. Bone marrow mesenchymal stem cells suppress IL-9 in adjuvant-induced arthritis. Autoimmunity. 2018;51(1):25–34.
46. Moradian H, Keshvari H, Fasehee H, et al. Combining NT3-overexpressing MSCs and PLGA microcarriers for brain tissue engineering: a potential tool for treatment of Parkinson’s disease. Mater Sci Eng C Mater Biol Appl. 2017:76:934-943.
47. Morandi F, Raffaghello L, Bianchi G, et al. Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. Stem Cells. 2008;26(5):1275–87.
48. Chen D, Fu W, Zhuang W, et al. Therapeutic effects of intranigral transplantation of mesenchymal stem cells in rat models of Parkinson’s disease. J Neurosci Res. 2017;95(3):907–17.
49. Beane OS, Fonseca VC, Cooper LL, et al. Impact of aging on the regenerative properties of bone marrow-, muscle-, and adipose-derived mesenchymal stem/stromal cells. PLoS One. 2014;9(12):e115963.
50. Schwerk A, Altschüler J, Roch M, et al. Adipose-derived human mesenchymal stem cells induce long-term neurogenic and anti-inflammatory effects and improve cognitive but not motor performance in a rat model of Parkinson’s disease. Regen Med. 2015;10(4):431–46.
51. Chen X, Yan L, Guo Z, et al. Adipose-derived mesenchymal stem cells promote the survival of fat grafts via crosstalk between the Nrf2 and TLR4 pathways. Cell Death Dis. 2016;7:e2369.
52. Zhou Y, Sun M, Li H, et al. Recovery of behavioral symptoms in hemi-parkinsonian rhesus monkeys through combined gene and stem cell therapy. Cytotherapy. 2013;15(4):467–80.
53. Heo JS, Choi Y, Kim HS, et al. Comparison of molecular profiles of human mesenchymal stem cells derived from bone marrow, umbilical cord blood, placenta and adipose tissue. Int J Mol Med. 2016;37(1):115–25.
54. Choi HS, Kim HJ, Oh JH, et al. Therapeutic potentials of human adipose-derived stem cells on the mouse model of Parkinson’s disease. Neurobiol Aging. 2015;36(10):2885–92.
55. Deane JA, Gualano RC, Gargett CE. Regenerating endometrium from stem/progenitor cells: is it abnormal in endometriosis, Asherman’s syndrome and infertility?. Curr Opin Obstet Gynecol. 2013;25(3):193–200.
56. Mutlu L, Hufnagel D, Taylor HS. The endometrium as a source of mesenchymal stem cells for regenerative medicine. Biol Reprod. 2015;92(6):138.
57. Wolff EF, Gao X, Yao KV, et al. Endometrial stem cell transplantation restores dopamine production in a Parkinson’s disease model. J Cell Mol Med. 2011;15(4):747–55.
58. Wolff EF, Mutlu L, Massasa EE, et al. Endometrial stem cell transplantation in MPTP‐exposed primates: an alternative cell source for treatment of P arkinson’s disease. J Cell Mol Med. 2015;19(1):249–56.
59. Bachoud-Lévi AC, Ferreira J, Massart R, et al. International guidelines for the treatment of Huntington’s disease. Front Neurol. 2019;10:710.
60. Allami M, Mohammad EJ, Alzzawi F, et al. Prevalence and antibiotic resistance pattern of pathogenic bacteria isolated from urinary tract infections in Qal’at Saleh Hospital, Iraq. Avicenna J Clin Microbiol Infect. 2021;8(4):117-122.
61. Jimenez-Sanchez M, Licitra F, Underwood BR, et al. Huntington’s disease: mechanisms of pathogenesis and therapeutic strategies. Cold Spring Harb Perspect Med. 2017;7(7):a024240.
62. Liang XS, Sun ZW, Thomas AM, et al. Mesenchymal Stem Cell Therapy for Huntington Disease: A Meta‐Analysis. Stem Cells Int. 2023;2023(1):1109967.
63. Yu-Taeger L, Stricker-Shaver J, Arnold K, et al. Intranasal administration of mesenchymal stem cells ameliorates the abnormal dopamine transmission system and inflammatory reaction in the R6/2 mouse model of Huntington disease. Cells. 2019;8(6):595.
64. Elbaz EM, Helmy HS, El-Sahar AE, et al. Lercanidipine boosts the efficacy of mesenchymal stem cell therapy in 3-NP-induced Huntington’s disease model rats via modulation of the calcium/calcineurin/NFATc4 and Wnt/β-catenin signalling pathways. Neurochem Int. 2019;131:104548.
65. Pakpoor J, Wotton CJ, Schmierer K, et al. Gender identity disorders and multiple sclerosis risk: a national record-linkage study. Mult Scler. 2016;22(13):1759–62.
66. Allami M, Bahreini M, Sharifmoghadam MR. Antibiotic resistance, phylogenetic typing, and virulence genes profile analysis of uropathogenic Escherichia coli isolated from patients in southern Iraq. J Appl Genet. 2022;63(2):401–412.
67. Cohen JA, Imrey PB, Planchon SM, et al. Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. Mult Scler. 2018;24(4):501–11.
68. Abi Chahine N, Wehbe T, Rashed J, et al. Autologous bone marrow derived stem cells for the treatment of multiple sclerosis. Int J stem cells. 2016;9(2):207-212.
69. Rivera FJ, Aigner L. Adult mesenchymal stem cell therapy for myelin repair in multiple sclerosis. Biol Res. 2012;45(3):257–68.
70. Dulamea A. Mesenchymal stem cells in multiple sclerosis-translation to clinical trials. J Med Life. 2015;8(1):24-7.
71. Mohammed EJ, Hasan KC, Allami M. Phylogenetic groups, serogroups and virulence factors of uropathogenic Escherichia coli isolated from patients with urinary tract infection in Baghdad, Iraq. Iran J Microbiol. 2022;14(4):445–457.
72. Yousefi F, Ebtekar M, Soleimani M, et al. Comparison of in vivo immunomodulatory effects of intravenous and intraperitoneal administration of adipose-tissue mesenchymal stem cells in experimental autoimmune encephalomyelitis (EAE). Int Immunopharmacol. 2013;17(3):608–16.
73. King BH, Navot N, Bernier R, et al. Update on diagnostic classification in autism. Curr Opin Psychiatry. 2014;27(2):105–9.
74. Lord C, Brugha TS, Charman T, et al. Autism spectrum disorder. Nat Rev Dis Primers. 2020;6(1):5.
75. Corcoran J, Berry A, Hill S. The lived experience of US parents of children with autism spectrum disorders: A systematic review and meta-synthesis. J Intellect Disabil. 2015;19(4):356–66.
76. Buescher AVS, Cidav Z, Knapp M, et al. Costs of autism spectrum disorders in the United Kingdom and the United States. JAMA Pediatr. 2014;168(8):721–8.
77. Yoo HJ. Understanding evidence-based practice for autism spectrum disorder: Korean practice clinical guidelines. J Korean Acad Child Adolesc Psychiatry. 2024;35(1):1.
Acute Phase of Experimental Epilepsy. Biomed Pharmacol J. 2022;15(1):91–115.
92. Zaidman M, Novak CB, Midha R, et al. Epidemiology of peripheral nerve and brachial plexus injuries in a trauma population. Can J Surg. 2024;67(3): E261-E268.
93. Dubový P. Wallerian degeneration and peripheral nerve conditions for both axonal regeneration and neuropathic pain induction. Ann Anat. 2011;193(4):267–75.
94. Hall S. Nerve repair: a neurobiologist’s view. J Hand Surg Br. 2001;26(2):129–36.
95. Ghayour MB, Abdolmaleki A, Fereidoni M. Use of stem cells in the regeneration of peripheral nerve injuries: an overview. Neurosci J Shefaye Khatam. 2015;3(1):84–98.
96. Jesuraj NJ, Santosa KB, Macewan MR, et al. Schwann cells seeded in acellular nerve grafts improve functional recovery. Muscle Nerve. 2014;49(2):267–76.
97. Faroni A, Terenghi G, Reid AJ. Adipose-derived stem cells and nerve regeneration: promises and pitfalls. Int Rev Neurobiol. 2013;108:121–36.
98. Murakami T, Fujimoto Y, Yasunaga Y, et al. Transplanted neuronal progenitor cells in a peripheral nerve gap promote nerve repair. Brain Res. 2003;974(1–2):17–24.
99. Gu S, Shen Y, Xu W, et al. Application of fetal neural stem cells transplantation in delaying denervated muscle atrophy in rats with peripheral nerve injury. Microsurgery. 2010;30(4):266–74.
100. Peng J, Wang Y, Zhang L, et al. Human umbilical cord Wharton’s jelly-derived mesenchymal stem cells differentiate into a Schwann-cell phenotype and promote neurite outgrowth in vitro. Brain Res Bull. 2011;84(3):235–43.
101. Zhang Q, Wu P, Chen F, et al. Brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor-transfected bone mesenchymal stem cells for the repair of peripheral nerve injury. Front Bioeng Biotechnol. 2020;8:874.
102. Oliveira JT, Mostacada K, de Lima S, et al. Bone marrow mesenchymal stem cell transplantation for improving nerve regeneration. Int Rev Neurobiol. 2013;108:59–77.
103. Yarjanli Z, MahdaviShahri N, MoghaddamMatin M, et al. In Vitro Histological Investigation of Interactions between Rat’s Mesenchymal Stem Cells and Human Gingival Matrix. J Mashhad Dent Sch. 2012;36(1):79-90.
104. Rooney GE, Moran C, McMahon SS, et al. Gene-modified mesenchymal stem cells express functionally active nerve growth factor on an engineered poly lactic glycolic acid (PLGA) substrate. Tissue Eng Part A. 2008;14(5):681–90.
105. Mo SJ, Zhong Q, Zhou YF, et al. Bone marrow-derived mesenchymal stem cells prevent the apoptosis of neuron-like PC12 cells via erythropoietin expression. Neurosci Lett. 2012;522(2):92–7.
106. Lindvall O, Kokaia Z. Stem cells for the treatment of neurological disorders. Nature. 2006;441(7097):1094–6.
107. Kadoya K, Tsukada S, Lu P, et al. Combined intrinsic and extrinsic neuronal mechanisms facilitate bridging axonal regeneration one year after spinal cord injury. Neuron. 2009;64(2):165–72.
108. Mothe AJ, Tator CH. Advances in stem cell therapy for spinal cord injury. J Clin Invest. 2012;122(11):3824–34.
109. Newsome PN, Johannessen I, Boyle S,
et al. Human cord blood-derived cells can differentiate into hepatocytes in the mouse liver with no evidence of cellular fusion. Gastroenterology. 2003;124(7):1891–900.
110. Syková E, Homola A, Mazanec R, et al. Autologous bone marrow transplantation in patients with subacute and chronic spinal cord injury. Cell Transplant. 2006;15(8–9):675–87.
111. Park HC, Shim YS, Ha Y, et al. Treatment of complete spinal cord injury patients by autologous bone marrow cell transplantation and administration of granulocyte-macrophage colony stimulating factor. Tissue Eng. 2005;11(5–6):913–22.
112. Dobkin BH. What matters in cellular transplantation for spinal cord injury: the cells, the rehabilitation, or the best mix? Neurorehabil Neural Repair. 2010;24(1):7–9.
113. Jendelová P, Herynek V, Urdziková L, et al. Magnetic resonance tracking of human CD34 progenitor cells separated by means of immunomagnetic selection and transplanted into injured rat brain. Cell Transplant. 2005;14(4):173–82.
114. Kishk NA, Gabr H, Hamdy S, et al. Case control series of intrathecal autologous bone marrow mesenchymal stem cell therapy for chronic spinal cord injury. Neurorehabil Neural Repair. 2010;24(8):702–8.
115. Park CW, Kim KS, Bae S, et al. Cytokine secretion profiling of human mesenchymal stem cells by antibody array. Int J stem cells. 2009;2(1):59-68.
116. Park JH, Kim DY, Sung IY, et al. Long-term results of spinal cord injury therapy using mesenchymal stem cells derived from bone marrow in humans. Neurosurgery. 2012;70(5):1238–47.
117. Andres RH, Guzman R, Ducray AD, et al. Cell replacement therapy for intracerebral hemorrhage. Neurosurg Focus. 2008;24(3–4):E16.
118. Adams Jr HP, Del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007;38(5):1655–711.
119. Bliss T, Guzman R, Daadi M, et al. Cell transplantation therapy for stroke. Stroke. 2007;38(2 Suppl):817–26.
120. Savitz SI, Dinsmore J, Wu J, et al. Neurotransplantation of fetal porcine cells in patients with basal ganglia infarcts: a preliminary safety and feasibility study. Cerebrovasc Dis. 2005;20(2):101–7.
121. Huang W, Mo X, Qin C, et al. Transplantation of differentiated bone marrow stromal cells promotes motor functional recovery in rats with stroke. Neurol Res. 2013;35(3):320–8.
122. Ghazavi H, Hoseini SJ, Ebrahimzadeh-Bideskan A, et al. Fibroblast growth factor type 1 (FGF1)-overexpressed adipose-derived mesenchaymal stem cells (AD-MSC FGF1) induce neuroprotection and functional recovery in a rat stroke model. Stem Cell Rev Rep. 2017;13(5):670–85.
123. Hoseini SJ, Ghazavi H, Forouzanfar F, et al. Fibroblast growth factor 1-transfected adipose-derived mesenchymal stem cells promote angiogenic proliferation. DNA Cell Biol. 2017;36(5):401–12.
124. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013;19(4):764–72.
125. Mohammed EJ, Allami M, Sharifmoghadam MR, et al. Relationship between antibiotic resistance patterns and O-serogroups in uropathogenic Escherichia coli strains isolated from Iraqi patients. Jundishapur J Microbiol. 2021;14(8); e118833.
126. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.
127. Teng J, Hejazi S, Badr CE, et al. Systemic anticancer neural stem cells in combination with a cardiac glycoside for glioblastoma therapy. Stem Cells. 2014;32(8):2021–32.
128. Pacioni S, D’Alessandris QG, Giannetti S, et al. Human mesenchymal stromal cells inhibit tumor growth in orthotopic glioblastoma xenografts. Stem Cell Res Ther. 2017;8(1):53.
129. Dickson P V, Hamner JB, Burger RA, et al. Intravascular administration of tumor tropic neural progenitor cells permits targeted delivery of interferon-β and restricts tumor growth in a murine model of disseminated neuroblastoma. J Pediatr Surg. 2007;42(1):48–53.
130. Sasportas LS, Kasmieh R, Wakimoto H, et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci U S A. 2009;106(12):4822–7.
131. Allami M, et al. Antibiotic resistance and its correlation with biofilm formation and virulence genes in Klebsiella pneumoniae isolated from wounds. J Appl Genet. 2024;65(4):925–935.
132. Bagci-Onder T, Du W, Figueiredo JL, et al. Targeting breast to brain metastatic tumours with death receptor ligand expressing therapeutic stem cells. Brain. 2015;138(Pt 6):1710–21.
133. Nakamizo A, Marini F, Amano T, et al. Human bone marrow–derived mesenchymal stem cells in the treatment of gliomas. Cancer Res. 2005;65(8):3307–18.
134. Hong X, Miller C, Savant-Bhonsale S, et al. Antitumor treatment using interleukin-12-secreting marrow stromal cells in an invasive glioma model. Neurosurgery. 2009;64(6):1139–46.
135. Ströjby S, Eberstål S, Svensson A, et al. Intratumorally implanted mesenchymal stromal cells potentiate peripheral immunotherapy against malignant rat gliomas. J Neuroimmunol. 2014;274(1–2):240–3.
136. Wang Y, Jiang T. Understanding high grade glioma: molecular mechanism, therapy and comprehensive management. Cancer Lett. 2013;331(2):139–46.
137. Stuckey DW, Hingtgen SD, Karakas N, et al. Engineering toxin-resistant therapeutic stem cells to treat brain tumors. Stem Cells. 2015;33(2):589–600.
138. Altaner C, Altanerova V, Cihova M, et al. Complete regression of glioblastoma by mesenchymal stem cells mediated prodrug gene therapy simulating clinical therapeutic scenario. Int J Cancer. 2014;134(6):1458–65.
139. Kim SK, Kim SU, Park IH, et al. Human neural stem cells target experimental intracranial medulloblastoma and deliver a therapeutic gene leading to tumor regression. Clin Cancer Res. 2006;12(18):5550–6.
140. Lee JY, Lee DH, Kim HA, et al. Double suicide gene therapy using human neural stem cells against glioblastoma: double safety measures. J Neurooncol. 2014;116(1):49–57.
141. Martinez-Quintanilla J, Bhere D, Heidari P, et al. Therapeutic efficacy and fate of bimodal engineered stem cells in malignant brain tumors. Stem Cells. 2013;31(8):1706–14.
142. Nawaz M, Fatima F, Vallabhaneni KC, et al. Extracellular vesicles: evolving factors in stem cell biology. Stem Cells Int. 2016;2016(1):1073140.
143. Lee HK, Finniss S, Cazacu S, et al. Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal. Oncotarget. 2013;4(2):346-61.
144. Pacioni S, D’Alessandris QG, Giannetti S, et al. Mesenchymal stromal cells loaded with paclitaxel induce cytotoxic damage in glioblastoma brain xenografts. Stem Cell Res Ther. 2015;6:194.
145. Levi AD, Okonkwo DO, Park P, et al. Emerging safety of intramedullary transplantation of human neural stem cells in chronic cervical and thoracic spinal cord injury. Neurosurgery. 2018;82(4):562–75.
146. Silvestro S, Bramanti P, Trubiani O, et al. Stem cells therapy for spinal cord injury: an overview of clinical trials. Int J Mol Sci. 2020;21(2):659.
147. Gao L, Peng Y, Xu W, et al. Progress in stem cell therapy for spinal cord injury. Stem Cells Int. 2020;2020(1):2853650.
148. Oh SK, Jeon SR. Current concept of stem cell therapy for spinal cord injury: A review. Korean J Neurotrauma. 2016;12(2):40-46.
149. Shao A, Tu S, Lu J, et al. Crosstalk between stem cell and spinal cord injury: pathophysiology and treatment strategies. Stem Cell Res Ther. 2019;10(1):238.
2. Wu YY, Gao YM, Feng T, et al. Enhancing functional recovery after spinal cord injury through neuroplasticity: a comprehensive review. Int J Mol Sci. 2025;26(14):6596.
3. Mohammadsadeghi H. The role of astrocytes in the central nervous system: physiological and pathophysiological conditions. Neurosci J Shefaye Khatam. 2021;9(2):119–39.
4. Sahab Negah S, Aligholi H, Mohammad Sadeghi S, et al. P39: Effect of Injured Brain Extract on Proliferation of Neural Stem/Progenitor Cells Cultured in a 3-dimensional Scaffold. Neurosci J Shefaye Khatam. 2014;2(4):Suppl. 3.
5. Hajali V, Moradi HR, Sahab Negah S. Neurotransmitters Play as a Key Role in Adult Neurogenesis. Neurosci J Shefaye Khatam. 2018;6(4):61–74.
6. Jabbarian M, Darvishi M, Barati DP, et al. Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells into Neuron-Like Cells Affected by Extract of Ginger Officinale. 2017; 5(2):1-10.
7. Webb AA, Ngan S, Fowler D. Spinal cord injury II: Prognostic indicators, standards of care, and clinical trials. Can Vet J. 2010;51(6):598-604.
8. Aktan F, Henness S, Tran VH, et al. Gingerol metabolite and a synthetic analogue CapsarolTM inhibit macrophage NF-κB-mediated iNOS gene expression and enzyme activity. Planta Med. 2006;72(08):727–34.
9. Rahman MM, Islam MR, Islam MT, et al. Stem cell transplantation therapy and neurological disorders: current status and future perspectives. Biology (Basel). 2022;11(1):147.
10. Chen S, et al. Clinical translational research on stem cell products: prospects and challenges. Signal Transduct Target Ther. 2026;11(1):178.
11. Yusoff NA, Abd Hamid Z, Budin SB, et al. Hematopoietic stem cell discovery: unveiling the historical and future perspective of colony-forming units assay. PeerJ. 2025;13: e18854.
12. Gage FH. Mammalian neural stem cells. Science. 2000;287(5457):1433–8.
13. Silvestris DA, De Luisi A 1 , Lucia Capobianco D, et al. Single-cell transcriptomic profiling of human fetal neural stem cells isolated from the subventricular zone. Front Cell Dev Biol. 2026;14:1740851.
14. Allami M, Al-Shammari AM, Neshati Z. Generation and characterization of Purkinje-like cells from differentiated mouse bone marrow mesenchymal stem cells. Iranian J War Pub Health. 2025;17(2):113-121.
15. Stafford N. Germany liberalises law on stem cell research. BMJ. 2008;336(7649):851.
16. Takabatake K, Tsujigiwa H , Song Yu, et al. The role of bone marrow-derived cells during ectopic bone formation of mouse femoral muscle in GFP mouse bone marrow transplantation model. Int J Med Sci. 2018;15(8):748–755.
17. Chang D, Fan T, Gao S, et al. Application of mesenchymal stem cell sheet to treatment of ischemic heart disease. Stem Cell Res Ther. 2021;12(1):384.
18. Lee BC, Kim HS, Shin TH, et al. PGE2 maintains self-renewal of human adult stem cells via EP2-mediated autocrine signaling and its production is regulated by cell-to-cell contact. Sci Rep. 2016;6:26298.
19. Tang Y, Zhou Y, Li HJ. Advances in mesenchymal stem cell exosomes: a review. Stem Cell Res Ther. 2021;12(1):71.
20. Margiana R, Markov A, Zekiy AO, et al. Clinical application of mesenchymal stem cell in regenerative medicine: a narrative review. Stem Cell Res Ther. 2022;13(1):366.
21. Hmadcha A, Martin-Montalvo A, Gauthier BR, et al. Therapeutic potential of mesenchymal stem cells for cancer therapy. Front Bioeng Biotechnol. 2020;8:43.
22. Haus DL, López-Velázquez L, Gold EM, et al. Transplantation of human neural stem cells restores cognition in an immunodeficient rodent model of traumatic brain injury. Exp Neurol. 2016;281:1–16.
23. Alnaji Z, Mohammed EJ, Allami M, et al. Multidrug-resistant Pseudomonas aeruginosa in wound and burn infections: resistance, virulence, serotypes and biofilm characteristics in Baghdad. J Umm Al-Qura Univ Appl Sci. 2026:1-15
24. Zhang C, Saatman KE, Royo NC, et al. Delayed transplantation of human neurons following brain injury in rats: a long-term graft survival and behavior study. J Neurotrauma. 2005;22(12):1456–74.
25. Clervius H, Baig M, Mahavadi A, et al. Human neural stem cell transplants to address multiple pathologies associated with traumatic brain injury. Neural Regen Res. 2019;14(10):1699–700.
26. Firouzabadi ED, Allami M, Mohammed EJ, et al. Detection of novel PPP1R1B::STARD3 fusion transcript in acute myeloid leukemia: a case report. J Med Case Rep. 2024;18(1):269.
27. Afhami M, Behnam-Rassouli M, Gorji A, et al. Isolation and culture of neural stem/progenitor cells from the hippocampal dentate gyrus of young adult and aged rats. Bio Protoc. 2023;13(19): e4843.
28. Baig MH, Ahmad K, Rabbani G, et al. Use of peptides for the management of Alzheimer’s disease: diagnosis and inhibition. Front Aging Neurosci. 2018;10:21.
29. Engel M, Do-Ha D, Munoz SS, et al. Common pitfalls of stem cell differentiation: a guide to improving protocols for neurodegenerative disease models and research. Cell Mol Life Sci. 2016;73(19):3693–709.
30. Jones SV, Kounatidis I. Nuclear factor-kappa B and Alzheimer disease, unifying genetic and environmental risk factors from cell to humans. Front Immunol. 2017;8:1805.
31. Shen Z, Li X, Bao X, et al. Microglia‐targeted stem cell therapies for Alzheimer disease: A preclinical data review. J Neurosci Res. 2017;95(12):2420–9.
32. Ebrahimikia Y, Darabi S, Rajaei F. Roles of Stem Cells in the Treatment of Alzheimer’s Disease. J Shahid Sadoughi Univ Med Sci. 2020;28(3):2431-2441.
33. Ra JC, Shin IS, Kim SH, et al. Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. Stem Cells Dev. 2011;20(8):1297–308.
34. Lee J, Kuroda S, Shichinohe H, et al. Migration and differentiation of nuclear fluorescence‐labeled bone marrow stromal cells after transplantation into cerebral infarct and spinal cord injury in mice. Neuropathology. 2003;23(3):169–80.
35. Kim KS, Kim HS, Park JM, et al. Long-term immunomodulatory effect of amniotic stem cells in an Alzheimer’s disease model. Neurobiol Aging. 2013;34(10):2408–20.
36. Naaldijk Y, Jaeger C, Fabian C, et al. Effect of systemic transplantation of bone marrow‐derived mesenchymal stem cells on neuropathology markers in APP/PS 1 Alzheimer mice. Neuropathol Appl Neurobiol. 2017;43(4):299–314.
37. Faghihi A, Joghataei MT, Darabi S, et al. Evaluation of Behavioral Effects of Trans-Resveratrol in the Hemi-Parkinsonian Rat Model. Anat Sci J. 2007;5(19):107–14.
38. Rangel-Barajas C, Coronel I, Florán B. Dopamine receptors and neurodegeneration. Aging Dis. 2015;6(5):349-368.
39. Zhang J, Wang X, Li J, et al. The preclinical research progress of stem cells therapy in Parkinson’s disease. Biomed Res Int. 2016;2016(1):5683097.
40. Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg psychiatry. 2008;79(4):368–76.
41. Nooraei MS, Noori-Zadeh A, Darabi S, et al. Low level of autophagy-related gene 10 (ATG10) expression in the 6-hydroxydopamine rat model of Parkinson’s disease. Iran Biomed J. 2018;22(1):15-21.
42. Choi H, Koh SH. Understanding the role of glycogen synthase kinase-3 in L-DOPA-induced dyskinesia in Parkinson’s disease. Expert Opin Drug Metab Toxicol. 2018;14(1):83–90.
43. Darabi S, Tiraihi T, Delshad A, et al. In vitro non-viral murine pro-neurotrophin 3 gene transfer into rat bone marrow stromal cells. J Neurol Sci. 2017;375:137–45.
44. Barachini S, Trombi L, Danti S, et al. Morpho-functional characterization of human mesenchymal stem cells from umbilical cord blood for potential uses in regenerative medicine. Stem Cells Dev. 2009;18(2):293–305.
45. Abd-Elhalem SS, Haggag NZ, El-Shinnawy NA. Bone marrow mesenchymal stem cells suppress IL-9 in adjuvant-induced arthritis. Autoimmunity. 2018;51(1):25–34.
46. Moradian H, Keshvari H, Fasehee H, et al. Combining NT3-overexpressing MSCs and PLGA microcarriers for brain tissue engineering: a potential tool for treatment of Parkinson’s disease. Mater Sci Eng C Mater Biol Appl. 2017:76:934-943.
47. Morandi F, Raffaghello L, Bianchi G, et al. Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. Stem Cells. 2008;26(5):1275–87.
48. Chen D, Fu W, Zhuang W, et al. Therapeutic effects of intranigral transplantation of mesenchymal stem cells in rat models of Parkinson’s disease. J Neurosci Res. 2017;95(3):907–17.
49. Beane OS, Fonseca VC, Cooper LL, et al. Impact of aging on the regenerative properties of bone marrow-, muscle-, and adipose-derived mesenchymal stem/stromal cells. PLoS One. 2014;9(12):e115963.
50. Schwerk A, Altschüler J, Roch M, et al. Adipose-derived human mesenchymal stem cells induce long-term neurogenic and anti-inflammatory effects and improve cognitive but not motor performance in a rat model of Parkinson’s disease. Regen Med. 2015;10(4):431–46.
51. Chen X, Yan L, Guo Z, et al. Adipose-derived mesenchymal stem cells promote the survival of fat grafts via crosstalk between the Nrf2 and TLR4 pathways. Cell Death Dis. 2016;7:e2369.
52. Zhou Y, Sun M, Li H, et al. Recovery of behavioral symptoms in hemi-parkinsonian rhesus monkeys through combined gene and stem cell therapy. Cytotherapy. 2013;15(4):467–80.
53. Heo JS, Choi Y, Kim HS, et al. Comparison of molecular profiles of human mesenchymal stem cells derived from bone marrow, umbilical cord blood, placenta and adipose tissue. Int J Mol Med. 2016;37(1):115–25.
54. Choi HS, Kim HJ, Oh JH, et al. Therapeutic potentials of human adipose-derived stem cells on the mouse model of Parkinson’s disease. Neurobiol Aging. 2015;36(10):2885–92.
55. Deane JA, Gualano RC, Gargett CE. Regenerating endometrium from stem/progenitor cells: is it abnormal in endometriosis, Asherman’s syndrome and infertility?. Curr Opin Obstet Gynecol. 2013;25(3):193–200.
56. Mutlu L, Hufnagel D, Taylor HS. The endometrium as a source of mesenchymal stem cells for regenerative medicine. Biol Reprod. 2015;92(6):138.
57. Wolff EF, Gao X, Yao KV, et al. Endometrial stem cell transplantation restores dopamine production in a Parkinson’s disease model. J Cell Mol Med. 2011;15(4):747–55.
58. Wolff EF, Mutlu L, Massasa EE, et al. Endometrial stem cell transplantation in MPTP‐exposed primates: an alternative cell source for treatment of P arkinson’s disease. J Cell Mol Med. 2015;19(1):249–56.
59. Bachoud-Lévi AC, Ferreira J, Massart R, et al. International guidelines for the treatment of Huntington’s disease. Front Neurol. 2019;10:710.
60. Allami M, Mohammad EJ, Alzzawi F, et al. Prevalence and antibiotic resistance pattern of pathogenic bacteria isolated from urinary tract infections in Qal’at Saleh Hospital, Iraq. Avicenna J Clin Microbiol Infect. 2021;8(4):117-122.
61. Jimenez-Sanchez M, Licitra F, Underwood BR, et al. Huntington’s disease: mechanisms of pathogenesis and therapeutic strategies. Cold Spring Harb Perspect Med. 2017;7(7):a024240.
62. Liang XS, Sun ZW, Thomas AM, et al. Mesenchymal Stem Cell Therapy for Huntington Disease: A Meta‐Analysis. Stem Cells Int. 2023;2023(1):1109967.
63. Yu-Taeger L, Stricker-Shaver J, Arnold K, et al. Intranasal administration of mesenchymal stem cells ameliorates the abnormal dopamine transmission system and inflammatory reaction in the R6/2 mouse model of Huntington disease. Cells. 2019;8(6):595.
64. Elbaz EM, Helmy HS, El-Sahar AE, et al. Lercanidipine boosts the efficacy of mesenchymal stem cell therapy in 3-NP-induced Huntington’s disease model rats via modulation of the calcium/calcineurin/NFATc4 and Wnt/β-catenin signalling pathways. Neurochem Int. 2019;131:104548.
65. Pakpoor J, Wotton CJ, Schmierer K, et al. Gender identity disorders and multiple sclerosis risk: a national record-linkage study. Mult Scler. 2016;22(13):1759–62.
66. Allami M, Bahreini M, Sharifmoghadam MR. Antibiotic resistance, phylogenetic typing, and virulence genes profile analysis of uropathogenic Escherichia coli isolated from patients in southern Iraq. J Appl Genet. 2022;63(2):401–412.
67. Cohen JA, Imrey PB, Planchon SM, et al. Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. Mult Scler. 2018;24(4):501–11.
68. Abi Chahine N, Wehbe T, Rashed J, et al. Autologous bone marrow derived stem cells for the treatment of multiple sclerosis. Int J stem cells. 2016;9(2):207-212.
69. Rivera FJ, Aigner L. Adult mesenchymal stem cell therapy for myelin repair in multiple sclerosis. Biol Res. 2012;45(3):257–68.
70. Dulamea A. Mesenchymal stem cells in multiple sclerosis-translation to clinical trials. J Med Life. 2015;8(1):24-7.
71. Mohammed EJ, Hasan KC, Allami M. Phylogenetic groups, serogroups and virulence factors of uropathogenic Escherichia coli isolated from patients with urinary tract infection in Baghdad, Iraq. Iran J Microbiol. 2022;14(4):445–457.
72. Yousefi F, Ebtekar M, Soleimani M, et al. Comparison of in vivo immunomodulatory effects of intravenous and intraperitoneal administration of adipose-tissue mesenchymal stem cells in experimental autoimmune encephalomyelitis (EAE). Int Immunopharmacol. 2013;17(3):608–16.
73. King BH, Navot N, Bernier R, et al. Update on diagnostic classification in autism. Curr Opin Psychiatry. 2014;27(2):105–9.
74. Lord C, Brugha TS, Charman T, et al. Autism spectrum disorder. Nat Rev Dis Primers. 2020;6(1):5.
75. Corcoran J, Berry A, Hill S. The lived experience of US parents of children with autism spectrum disorders: A systematic review and meta-synthesis. J Intellect Disabil. 2015;19(4):356–66.
76. Buescher AVS, Cidav Z, Knapp M, et al. Costs of autism spectrum disorders in the United Kingdom and the United States. JAMA Pediatr. 2014;168(8):721–8.
77. Yoo HJ. Understanding evidence-based practice for autism spectrum disorder: Korean practice clinical guidelines. J Korean Acad Child Adolesc Psychiatry. 2024;35(1):1.
Acute Phase of Experimental Epilepsy. Biomed Pharmacol J. 2022;15(1):91–115.
92. Zaidman M, Novak CB, Midha R, et al. Epidemiology of peripheral nerve and brachial plexus injuries in a trauma population. Can J Surg. 2024;67(3): E261-E268.
93. Dubový P. Wallerian degeneration and peripheral nerve conditions for both axonal regeneration and neuropathic pain induction. Ann Anat. 2011;193(4):267–75.
94. Hall S. Nerve repair: a neurobiologist’s view. J Hand Surg Br. 2001;26(2):129–36.
95. Ghayour MB, Abdolmaleki A, Fereidoni M. Use of stem cells in the regeneration of peripheral nerve injuries: an overview. Neurosci J Shefaye Khatam. 2015;3(1):84–98.
96. Jesuraj NJ, Santosa KB, Macewan MR, et al. Schwann cells seeded in acellular nerve grafts improve functional recovery. Muscle Nerve. 2014;49(2):267–76.
97. Faroni A, Terenghi G, Reid AJ. Adipose-derived stem cells and nerve regeneration: promises and pitfalls. Int Rev Neurobiol. 2013;108:121–36.
98. Murakami T, Fujimoto Y, Yasunaga Y, et al. Transplanted neuronal progenitor cells in a peripheral nerve gap promote nerve repair. Brain Res. 2003;974(1–2):17–24.
99. Gu S, Shen Y, Xu W, et al. Application of fetal neural stem cells transplantation in delaying denervated muscle atrophy in rats with peripheral nerve injury. Microsurgery. 2010;30(4):266–74.
100. Peng J, Wang Y, Zhang L, et al. Human umbilical cord Wharton’s jelly-derived mesenchymal stem cells differentiate into a Schwann-cell phenotype and promote neurite outgrowth in vitro. Brain Res Bull. 2011;84(3):235–43.
101. Zhang Q, Wu P, Chen F, et al. Brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor-transfected bone mesenchymal stem cells for the repair of peripheral nerve injury. Front Bioeng Biotechnol. 2020;8:874.
102. Oliveira JT, Mostacada K, de Lima S, et al. Bone marrow mesenchymal stem cell transplantation for improving nerve regeneration. Int Rev Neurobiol. 2013;108:59–77.
103. Yarjanli Z, MahdaviShahri N, MoghaddamMatin M, et al. In Vitro Histological Investigation of Interactions between Rat’s Mesenchymal Stem Cells and Human Gingival Matrix. J Mashhad Dent Sch. 2012;36(1):79-90.
104. Rooney GE, Moran C, McMahon SS, et al. Gene-modified mesenchymal stem cells express functionally active nerve growth factor on an engineered poly lactic glycolic acid (PLGA) substrate. Tissue Eng Part A. 2008;14(5):681–90.
105. Mo SJ, Zhong Q, Zhou YF, et al. Bone marrow-derived mesenchymal stem cells prevent the apoptosis of neuron-like PC12 cells via erythropoietin expression. Neurosci Lett. 2012;522(2):92–7.
106. Lindvall O, Kokaia Z. Stem cells for the treatment of neurological disorders. Nature. 2006;441(7097):1094–6.
107. Kadoya K, Tsukada S, Lu P, et al. Combined intrinsic and extrinsic neuronal mechanisms facilitate bridging axonal regeneration one year after spinal cord injury. Neuron. 2009;64(2):165–72.
108. Mothe AJ, Tator CH. Advances in stem cell therapy for spinal cord injury. J Clin Invest. 2012;122(11):3824–34.
109. Newsome PN, Johannessen I, Boyle S,
et al. Human cord blood-derived cells can differentiate into hepatocytes in the mouse liver with no evidence of cellular fusion. Gastroenterology. 2003;124(7):1891–900.
110. Syková E, Homola A, Mazanec R, et al. Autologous bone marrow transplantation in patients with subacute and chronic spinal cord injury. Cell Transplant. 2006;15(8–9):675–87.
111. Park HC, Shim YS, Ha Y, et al. Treatment of complete spinal cord injury patients by autologous bone marrow cell transplantation and administration of granulocyte-macrophage colony stimulating factor. Tissue Eng. 2005;11(5–6):913–22.
112. Dobkin BH. What matters in cellular transplantation for spinal cord injury: the cells, the rehabilitation, or the best mix? Neurorehabil Neural Repair. 2010;24(1):7–9.
113. Jendelová P, Herynek V, Urdziková L, et al. Magnetic resonance tracking of human CD34 progenitor cells separated by means of immunomagnetic selection and transplanted into injured rat brain. Cell Transplant. 2005;14(4):173–82.
114. Kishk NA, Gabr H, Hamdy S, et al. Case control series of intrathecal autologous bone marrow mesenchymal stem cell therapy for chronic spinal cord injury. Neurorehabil Neural Repair. 2010;24(8):702–8.
115. Park CW, Kim KS, Bae S, et al. Cytokine secretion profiling of human mesenchymal stem cells by antibody array. Int J stem cells. 2009;2(1):59-68.
116. Park JH, Kim DY, Sung IY, et al. Long-term results of spinal cord injury therapy using mesenchymal stem cells derived from bone marrow in humans. Neurosurgery. 2012;70(5):1238–47.
117. Andres RH, Guzman R, Ducray AD, et al. Cell replacement therapy for intracerebral hemorrhage. Neurosurg Focus. 2008;24(3–4):E16.
118. Adams Jr HP, Del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007;38(5):1655–711.
119. Bliss T, Guzman R, Daadi M, et al. Cell transplantation therapy for stroke. Stroke. 2007;38(2 Suppl):817–26.
120. Savitz SI, Dinsmore J, Wu J, et al. Neurotransplantation of fetal porcine cells in patients with basal ganglia infarcts: a preliminary safety and feasibility study. Cerebrovasc Dis. 2005;20(2):101–7.
121. Huang W, Mo X, Qin C, et al. Transplantation of differentiated bone marrow stromal cells promotes motor functional recovery in rats with stroke. Neurol Res. 2013;35(3):320–8.
122. Ghazavi H, Hoseini SJ, Ebrahimzadeh-Bideskan A, et al. Fibroblast growth factor type 1 (FGF1)-overexpressed adipose-derived mesenchaymal stem cells (AD-MSC FGF1) induce neuroprotection and functional recovery in a rat stroke model. Stem Cell Rev Rep. 2017;13(5):670–85.
123. Hoseini SJ, Ghazavi H, Forouzanfar F, et al. Fibroblast growth factor 1-transfected adipose-derived mesenchymal stem cells promote angiogenic proliferation. DNA Cell Biol. 2017;36(5):401–12.
124. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013;19(4):764–72.
125. Mohammed EJ, Allami M, Sharifmoghadam MR, et al. Relationship between antibiotic resistance patterns and O-serogroups in uropathogenic Escherichia coli strains isolated from Iraqi patients. Jundishapur J Microbiol. 2021;14(8); e118833.
126. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.
127. Teng J, Hejazi S, Badr CE, et al. Systemic anticancer neural stem cells in combination with a cardiac glycoside for glioblastoma therapy. Stem Cells. 2014;32(8):2021–32.
128. Pacioni S, D’Alessandris QG, Giannetti S, et al. Human mesenchymal stromal cells inhibit tumor growth in orthotopic glioblastoma xenografts. Stem Cell Res Ther. 2017;8(1):53.
129. Dickson P V, Hamner JB, Burger RA, et al. Intravascular administration of tumor tropic neural progenitor cells permits targeted delivery of interferon-β and restricts tumor growth in a murine model of disseminated neuroblastoma. J Pediatr Surg. 2007;42(1):48–53.
130. Sasportas LS, Kasmieh R, Wakimoto H, et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci U S A. 2009;106(12):4822–7.
131. Allami M, et al. Antibiotic resistance and its correlation with biofilm formation and virulence genes in Klebsiella pneumoniae isolated from wounds. J Appl Genet. 2024;65(4):925–935.
132. Bagci-Onder T, Du W, Figueiredo JL, et al. Targeting breast to brain metastatic tumours with death receptor ligand expressing therapeutic stem cells. Brain. 2015;138(Pt 6):1710–21.
133. Nakamizo A, Marini F, Amano T, et al. Human bone marrow–derived mesenchymal stem cells in the treatment of gliomas. Cancer Res. 2005;65(8):3307–18.
134. Hong X, Miller C, Savant-Bhonsale S, et al. Antitumor treatment using interleukin-12-secreting marrow stromal cells in an invasive glioma model. Neurosurgery. 2009;64(6):1139–46.
135. Ströjby S, Eberstål S, Svensson A, et al. Intratumorally implanted mesenchymal stromal cells potentiate peripheral immunotherapy against malignant rat gliomas. J Neuroimmunol. 2014;274(1–2):240–3.
136. Wang Y, Jiang T. Understanding high grade glioma: molecular mechanism, therapy and comprehensive management. Cancer Lett. 2013;331(2):139–46.
137. Stuckey DW, Hingtgen SD, Karakas N, et al. Engineering toxin-resistant therapeutic stem cells to treat brain tumors. Stem Cells. 2015;33(2):589–600.
138. Altaner C, Altanerova V, Cihova M, et al. Complete regression of glioblastoma by mesenchymal stem cells mediated prodrug gene therapy simulating clinical therapeutic scenario. Int J Cancer. 2014;134(6):1458–65.
139. Kim SK, Kim SU, Park IH, et al. Human neural stem cells target experimental intracranial medulloblastoma and deliver a therapeutic gene leading to tumor regression. Clin Cancer Res. 2006;12(18):5550–6.
140. Lee JY, Lee DH, Kim HA, et al. Double suicide gene therapy using human neural stem cells against glioblastoma: double safety measures. J Neurooncol. 2014;116(1):49–57.
141. Martinez-Quintanilla J, Bhere D, Heidari P, et al. Therapeutic efficacy and fate of bimodal engineered stem cells in malignant brain tumors. Stem Cells. 2013;31(8):1706–14.
142. Nawaz M, Fatima F, Vallabhaneni KC, et al. Extracellular vesicles: evolving factors in stem cell biology. Stem Cells Int. 2016;2016(1):1073140.
143. Lee HK, Finniss S, Cazacu S, et al. Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal. Oncotarget. 2013;4(2):346-61.
144. Pacioni S, D’Alessandris QG, Giannetti S, et al. Mesenchymal stromal cells loaded with paclitaxel induce cytotoxic damage in glioblastoma brain xenografts. Stem Cell Res Ther. 2015;6:194.
145. Levi AD, Okonkwo DO, Park P, et al. Emerging safety of intramedullary transplantation of human neural stem cells in chronic cervical and thoracic spinal cord injury. Neurosurgery. 2018;82(4):562–75.
146. Silvestro S, Bramanti P, Trubiani O, et al. Stem cells therapy for spinal cord injury: an overview of clinical trials. Int J Mol Sci. 2020;21(2):659.
147. Gao L, Peng Y, Xu W, et al. Progress in stem cell therapy for spinal cord injury. Stem Cells Int. 2020;2020(1):2853650.
148. Oh SK, Jeon SR. Current concept of stem cell therapy for spinal cord injury: A review. Korean J Neurotrauma. 2016;12(2):40-46.
149. Shao A, Tu S, Lu J, et al. Crosstalk between stem cell and spinal cord injury: pathophysiology and treatment strategies. Stem Cell Res Ther. 2019;10(1):238.
| Files | ||
| Issue | Vol 20 No 3 (2026) | |
| Section | Review Article(s) | |
| Keywords | ||
| Mesenchymal stem cells; Neural stem cells; Neurodegenerative disorders; Central nervous system | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Allami M, Alnaji Z, Jassim Mohammed E. Mesenchymal Stem Cells in Neurodegenerative Disorders: A Review of Current Evidence and Therapeutic Perspectives. Int J Hematol Oncol Stem Cell Res. 2026;20(3):302-330.
